Amalio Telenti

Dr. Amalio Telenti

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2007 in Science
Verified
Journal Article
Closed access
PDF file
JFJacques Fellay
Jacques Fellay
KSKevin V. Shianna
Kevin V. Shianna
DGDongliang Ge
Dongliang Ge
SCSara Colombo
Sara Colombo
BLBruno Ledergerber
Bruno Ledergerber
DGDavid B. Goldstein
David B. Goldstein
Understanding why some people establish and maintain effective control of HIV-1 and others do not is a priority in the effort to develop new treatments for HIV/AIDS. Using a whole-genome association strategy, we identified polymorphisms that explain nearly 15% of the variation among individuals in viral load during the asymptomatic set-point period of infection. One of these is found within an endogenous retroviral element and is associated with major histocompatibility allele human leukocyte antigen ( HLA )– B*5701 , whereas a second is located near the HLA-C gene. An additional analysis of the time to HIV disease progression implicated two genes, one of which encodes an RNA polymerase I subunit. These findings emphasize the importance of studying human genetic variation as a guide to combating infectious agents.

23 December 2021 in Nature
Verified
Journal Article
Closed access
ECElisabetta Cameroni
Elisabetta Cameroni
JBJohn E. Bowen
John E. Bowen
LRLaura E. Rosen
Laura E. Rosen
CSChristian Saliba
Christian Saliba
SZSamantha K. Zepeda
Samantha K. Zepeda
DCDavide Corti
Davide Corti

26 November 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JZJames Y Zou
James Y Zou
MHMikael Huss
Mikael Huss
AAAbubakar Abid
Abubakar Abid
PMPejman Mohammadi
Pejman Mohammadi
ATAli Torkamani
Ali Torkamani
Amalio TelentiAmalio Telenti
Amalio Telenti

14 July 2021 in Nature
Verified
Journal Article
Closed access
PDF file
TSTyler N. Starr
Tyler N. Starr
NCNadine Czudnochowski
Nadine Czudnochowski
ZLZhuoming Liu
Zhuoming Liu
FZFabrizia Zatta
Fabrizia Zatta
YPYoung-Jun Park
Young-Jun Park
GSGyorgy Snell
Gyorgy Snell

6 March 2017 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TLTao Long
Tao Long
MHMichael Hicks
Michael Hicks
HYHung-Chun Yu
Hung-Chun Yu
WBWilliam H Biggs
William H Biggs
EKEwen F Kirkness
Ewen F Kirkness
Amalio TelentiAmalio Telenti
Amalio Telenti

6 August 2021 in Science
Verified
Journal Article
Open access
MMMatthew McCallum
Matthew McCallum
JBJessica Bassi
Jessica Bassi
AMAnna De Marco
Anna De Marco
ACAlex Chen
Alex Chen
AWAlexandra C. Walls
Alexandra C. Walls
DVDavid Veesler
David Veesler
SARS-CoV-2 from alpha to epsilon: As battles to contain the COVID-19 pandemic continue, attention is focused on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that have been deemed variants of concern because they are resistant to antibodies elicited by infection or vaccination or they increase transmissibility or disease severity. Three papers used functional and structural studies to explore how mutations in the viral spike protein affect its ability to infect host cells and to evade host immunity. Gobeil et al . looked at a variant spike protein involved in transmission between minks and humans, as well as the B1.1.7 (alpha), B.1.351 (beta), and P1 (gamma) spike variants; Cai et al . focused on the alpha and beta variants; and McCallum et al . discuss the properties of the spike protein from the B1.1.427/B.1.429 (epsilon) variant. Together, these papers show a balance among mutations that enhance stability, those that increase binding to the human receptor ACE2, and those that confer resistance to neutralizing antibodies. —VV